Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Wave Life Sciences Ltd. (WVE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
08/23/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"WAVE LIFE SCIENCES LTD. 2021 EQUITY INCENTIVE PLAN, AS AMENDED",
"WAVE LIFE SCIENCES LTD. 2019 EMPLOYEE SHARE PURCHASE PLAN, AS AMENDED The following constitute the provisions of the 2019 Employee Share Purchase Plan, as amended of Wave Life Sciences Ltd. . 1. Purpose . The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Ordinary Shares in the capital of the Company. It is the intention of the Company to have the Plan qualify as an “Employee Stock Purchase Plan” under Section 423 of the Code. The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the requirements of that section of the Code. 2. Definitions . “ Board ” shall mean the Board of Directors of the Company as constituted at any time, or a committee ..."
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Investor presentation, Quarterly results
Docs: "Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
05/23/2023 8-K Investor presentation
Docs: "Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia",
"Corporate Presentation of Wave Life Sciences Ltd."
05/05/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
05/03/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update",
"Corporate Presentation of Wave Life Sciences Ltd."
04/28/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/14/2023 SC 13G/A BB BIOTECH AG reports a 5.2% stake in WAVE LIFE SCIENCES LTD.
02/14/2023 SC 13G/A 683 Capital Management, LLC reports a 6.9% stake in Wave Life Sciences Ltd.
02/14/2023 SC 13G/A MAVERICK CAPITAL LTD reports a 8.2% stake in Wave Life Sciences Ltd.
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/30/2023 SC 13G GSK PLC reports a 11% stake in Wave Life Sciences Ltd.
01/30/2023 8-K Entry into a Material Definitive Agreement, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/09/2023 8-K Investor presentation
Docs: "Investor Presentation of Wave Life Sciences Ltd."
12/22/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/19/2022 8-K/A Quarterly results
12/19/2022 8-K Quarterly results
12/13/2022 8-K Quarterly results
12/08/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/15/2022 8-K Quarterly results
11/10/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update"
10/04/2022 8-K Investor presentation
Docs: "Corporate Presentation of Wave Life Sciences Ltd.",
"Corporate Presentation of Wave Life Sciences Ltd."
09/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event"
09/26/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/20/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington's Disease"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy